Select Page

BLADDERBladder Urothelial cancer (UC) accounts for about 90% of all bladder or urinary tract cancers. UC becomes harder to treat as it advances, resulting in a 5-year survival rate of only 5% for metastatic stage. Given the poor prognosis for these advanced patients, there is a high need for additional treatment options. Systemic chemotherapy is the standard approach for the initial treatment of patients with inoperable locally advanced or metastatic urothelial malignancies.

Capitalizing on our unique expertise in the Bladder Cancer market and in patient chart-based research, BLADDERsyndiTrackTM, our Bladder Urothelial Carcinoma syndicated study uses real-world data to monitor the evolution of UC management.

Example of recent release:
  • Data from April 2021 in FR, UK, DE, ES, IT
  • 359 Onco-Hematologists
  • 2,129 real-world patient charts analyzed
More information about the Bladder cancer syndicated study?
  • Objectives
  • Benefits
  • Samples
  • Scope
  • Types of data collected
  • Dates of research waves

Fill in the form and we will be in touch shortly. 👉